MaxCyte (MXCT) Q3 2024 earnings summary

Executive summary

• Q3 2024 total revenue was $8.2 million, up 2% year-over-year, with core revenue rising 23% to $8.1 million, driven by strong cell therapy performance.

• Six new Strategic Platform License (SPL) agreements were signed in 2024, a record, bringing the total to 29 and expanding the customer base.

• Management increased 2024 core revenue growth guidance and implemented operational discipline and leadership enhancements to support growth.

• Cash, cash equivalents, and investments totaled $196.6 million as of September 30, 2024, with no debt.

• Net loss for Q3 2024 was $11.6 million; for the nine months ended September 30, 2024, net loss was $30.5 million.

Financial highlights

• Q3 2024 total revenue was $8.2 million, up 2% year-over-year; core revenue was $8.1 million, up 23%.

• Cell therapy revenue grew 39% year-over-year to $6.5 million; drug discovery revenue declined 14% to $1.6 million.

• Instrument revenue was $1.8 million, lease revenue $2.5 million, and PA revenue $3.4 million (up 54% year-over-year).

• Gross margin for Q3 2024 was 76% (GAAP), down from 90%, due to a one-time inventory write-off; non-GAAP adjusted gross margin was 85%.

• Operating expenses for Q3 2024 were $20.3 million, down from $21.2 million year-over-year.

Outlook and guidance

• Full-year 2024 core revenue is expected to grow at least 5% over 2023.

• SPL program-related revenue guidance remains at approximately $6 million for 2024, with no additional milestone payments expected.

• Year-end 2024 cash, cash equivalents, and investments projected at approximately $185 million.

• Continued investment planned in R&D, sales, marketing, and product development, with near-term operating losses expected.